Evaluation of the efficacy of the AstrazenicaCovid 19 vaccine to develop IgG antibody andits level based on th12 weeks program. Also to follow the changes of markers ofcoagulation (D-dimer) after vaccination compared to the basic level. A cardiologyconsultant will follow D-Dimer results to be managed properly if there is a need. As itis expected to receive Sinopharm vaccine there will be comparison between results of thetwo types of vaccine. To our knowledge this will be the first study done on Egyptianpopulation.

SARS-CoV2 is responsible for a pandemic that has been evolving for approximately 18months. The virus' capacity for dissemination and its virulence are responsible forsignificant morbidity and mortality. The initial lack of knowledge of the pathogen and ofthe pathophysiology underlying the potential severity of the disease, particularly in therespiratory tract, led to numerous therapeutic attempts in this emergency context,centered on the control of an obviously exaggerated inflammatory response. A large numberof studies remained of insufficient quality to lead to relevant and applicableconclusions. Secondly, the benefit of corticosteroid therapy has been demonstrated in twotrials. Although Dexamethasone remains the only corticosteroid to improve survival, theseresults have reinforced the hypothesis of the interest of treatments reducing theinflammatory response, particularly cytokine. The widespread use, in the absence ofscientific data, of interleukin-6 receptor inhibitors (Sarilumab and Tocilizumab) hasbeen structured around studies whose results remain uncertain to this day because of theheterogeneity of the population treated and the results observed. A possible survivalbenefit seems to emerge for resuscitation patients who have not yet required invasiveventilation, the other situations being probably associated with the absence of effect oreven the potential danger of this treatment. Tocilizumab is notably associated in theliterature with the risk of secondary infections and mucosal healing abnormalities,favoring bleeding complications and digestive perforations. The objective of this studyis to evaluate the risk of digestive complications (hemorrhage, perforation,diverticulitis) and infectious complications related to the use of Tocilizumab accordingto the severity of the patients.

This is an open label randomized controlled clinical trial which was designed to confirmthe potential efficacy and safety of favipiravir in the management of patients with mildto moderate COVID-19 compared to best supportive care.

To explore the efficacy of treatment of pulmonary cytokine storm induced by SARS-CoV2with a monoclonal antibody to IL-2 (Basiliximab) in addition to current standard of carevs current standard of care with the primary efficacy endpoint being the proportion ofsubjects alive and free of ventilator support, defined as intubation and requiringmechanical ventilation, at Day 28 from time of randomization.

The 2020 COVID-19 pandemic, which began spreading on January 24, 2020 in France, hasrequired a profound and rapid reorganization of the health system, based in particular oninternal hospital reorganizations of front-line establishments, deprogramming ofnon-urgent activities, and transfers of non-covid19 patients to 2nd line facilities.Beyond the immediate impact on the management of patients infected with COVID-19, thisreorganization may have reduced the capacity of management for patients requiring urgentor semi-urgent intervention, or may have postponed some necessary care. The isolation ofpatients at home may also have resulted in lower compliance to therapy and medicaltreatments and may have contributed to decompensation.At the end of this crisis, the different organizational responses in France should beevaluated to identify the consequences and the areas for improvement in order to beprepared for future exceptional health situations. This investigation on healthcaresystems confronted to an exceptional health situation thus seeks to determine if theprofound reorganizations implemented during this health crisis have indirect effects onthe performance of care, in particular if there is a destabilization of the care systems(emergency, semi-emergency and chronic), a loss of chance for the patients and ifinnovative care paths have emerged.

Study Design: This is a double-blind, placebo-controlled, Phase 3 clinical efficacy studyevaluating NONS in adult volunteers as a treatment for high-risk asymptomatic andsymptomatic individuals with mild COVID-19 infection. thru facility).

The study aims to investigate (1) if COVID-19 vaccine impacts on blood pressure, (2) theextent of impact on blood pressure (if any), and (3) which groups of subjects are moresusceptible to be affected by COVID-19 vaccine on blood

To investigate short-term effect of COVID-19 vaccination on blood pressure by conducting24-hour ABPM

To measure the immunization rate (seroneutralization) in a population of exposed hospitalworkers (nursing staff assigned to dedicated COVID-19 care units, laboratory staffhandling COVID-19 samples).

SATS is a single site feasibility study to assess the practical and psychologicalfeasibility of using rapid COVID antibody testing of blood obtained from fingertippin-pricks.